Header Logo

Connection

WILLIAM G WIERDA to Myeloid Cell Leukemia Sequence 1 Protein

Back to Details
This is a "connection" page, showing publications WILLIAM G WIERDA has written about Myeloid Cell Leukemia Sequence 1 Protein.
WILLIAM G WIERDA
Connection Strength
0.903
Myeloid Cell Leukemia Sequence 1 Protein
  1. AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2020 07 15; 26(14):3856-3867.
    View in: PubMed
    Score: 0.155
  2. Induction of apoptosis by MCL-1 inhibitors in chronic lymphocytic leukemia cells. Leuk Lymphoma. 2019 12; 60(12):3063-3066.
    View in: PubMed
    Score: 0.148
  3. Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia. Leukemia. 2019 07; 33(7):1663-1674.
    View in: PubMed
    Score: 0.145
  4. Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia. Neoplasia. 2014 Dec; 16(12):1036-46.
    View in: PubMed
    Score: 0.108
  5. Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies. Clin Cancer Res. 2023 01 17; 29(2):446-457.
    View in: PubMed
    Score: 0.048
  6. Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells. Leukemia. 2022 06; 36(6):1596-1608.
    View in: PubMed
    Score: 0.045
  7. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer Cell. 2019 10 14; 36(4):369-384.e13.
    View in: PubMed
    Score: 0.038
  8. Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells. Oncotarget. 2017 Mar 07; 8(10):16259-16274.
    View in: PubMed
    Score: 0.032
  9. Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia. Leukemia. 2012 Aug; 26(8):1812-20.
    View in: PubMed
    Score: 0.022
  10. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012 Feb 10; 30(5):488-96.
    View in: PubMed
    Score: 0.022
  11. Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. Blood. 2011 Jan 06; 117(1):156-64.
    View in: PubMed
    Score: 0.020
  12. Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells. Blood. 2010 Aug 19; 116(7):1083-91.
    View in: PubMed
    Score: 0.020
  13. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 2009 Nov 05; 114(19):4150-7.
    View in: PubMed
    Score: 0.019
  14. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 07; 113(19):4637-45.
    View in: PubMed
    Score: 0.018
  15. AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood. 2009 Jan 01; 113(1):149-53.
    View in: PubMed
    Score: 0.018
  16. Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood. 2008 Sep 01; 112(5):1912-22.
    View in: PubMed
    Score: 0.017
  17. Mechanisms of cell death of chronic lymphocytic leukemia lymphocytes by RNA-directed agent, 8-NH2-adenosine. Clin Cancer Res. 2005 Sep 15; 11(18):6745-52.
    View in: PubMed
    Score: 0.014
  18. Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP. Blood. 2005 Jun 01; 105(11):4455-62.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.